Literature DB >> 6187620

Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture.

M Namba, T Miyoshi, T Kanamori, M Nobuhara, T Kimoto, S Ogawa.   

Abstract

The growth inhibitory effects of the combination of 5-fluorouracil (5-FU) and human fibroblast interferon on human neoplastic cell lines and normal human fibroblasts were examined. The neoplastic cell lines used were HeLa (cervical carcinoma), MCF-7 (mammary carcinoma), WI-38 CT-1 (embryonic lung fibroblasts transformed in culture by 60Co gamma-ray irradiation), KMM-1 (myeloma), and Raji (Burkitt's lymphoma). The normal human cell line used was WI-38. The growth inhibitory effects were determined by measuring colony formation for HeLa, MCF-7, WI-38 CT-1, and WI-38 cells, and by measuring cell growth for KMM-1 and Raji cells. Each cell line showed different sensitivities to 5-FU or interferon. The combination of 5-FU and interferon showed synergistic inhibitory effects on the growth of HeLa, WI-38 CT-1, KMM-1, and Raji cells. Neither synergistic nor additive growth inhibitory effects of the combination of 5-FU and interferon were observed in MCF-7 and WI-38 cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6187620

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  8 in total

1.  Combined effect of 5-fluorouracil and interferon on experimental liver metastases of rat colon carcinoma.

Authors:  R L Marquet; J Jeekel
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

2.  Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrah ydr o-2H-1 , 3,2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro.

Authors:  J S Kovach; P A Svingen
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

Authors:  H O Klein; G Golbach; P Voigt; C Coerper; C Bernhardt
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.

Authors:  M H Huber; M Shirinian; S M Lippman; I W Dimery; R A Frankenthaler; W K Hong
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.

Authors:  C J Punt; P H de Mulder; J T Burghouts; D J Wagener
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.

Authors:  B R Murphy; S M Rynard; L H Einhorn; P J Loehrer
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

7.  A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer.

Authors:  M Trudeau; A Zukiwski; A Langleben; G Boos; G Batist
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Survival, response and immune effects in a prospectively randomized study of dose strategy for alpha-N1 interferon.

Authors:  H K Silver; J M Connors; S Kong; K A Karim; J J Spinelli
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.